MicroPort® EP and Stereotaxis Collaborate to Advance Innovation and Adoption of Robotic Electrophysiology in China

Shanghai, China, 30 August, 2021 – Shanghai MicroPort® EP MedTech Co., Ltd (MicroPort® EP) and Stereotaxis (NYSE: STXS) today announced a broad collaboration to advance technology innovation and commercial adoption of robotics in electrophysiology in China.

The agreement brings together MicroPort EP’s commercial and product leadership in China’s electrophysiology market with Stereotaxis’ advanced Robotic Magnetic Navigation technology. As part of the collaboration, MicroPort® EP will become the exclusive distributor of Robotic Magnetic Navigation technology for electrophysiology in China.

MicroPort® EP will pursue regulatory approvals for Stereotaxis’ latest innovations including the Genesis RMN® system and proprietary magnetic ablation catheter. The companies will integrate Stereotaxis’ robotic systems with MicroPort® EP’s Columbus® mapping system, allowing physicians to benefit from the combination of both technologies. Both parties will also work together to develop a family of cardiac ablation and diagnostic catheters.

Stereotaxis, established in 1990, is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. These technologies help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis launched the world’s first Robotic Magnetic Navigation system Niobe® in 2003, and the updated version Genesis RMN® system received FDA approval in 2020. Core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, China, Japan, Canada, and elsewhere.

Prof. Jin Qi of Ruijin Hospital commented, “I am very excited by the promise of this collaboration. Having completed nearly 2,000 robotic ablations myself, I deeply understand the value of robotic technology and appreciate how this partnership will expand broad access to these benefits for hospitals, physicians and their patients across China.”

The agreement further advances MicroPort® EP’s pivotal role in China’s electrophysiology market by enabling it to develop and offer a highly differentiated product portfolio. The agreement builds upon the increasing interest and adoption Stereotaxis has experienced in China, is expected to significantly accelerate adoption, and supports Stereotaxis’s strategy of building a robust open ecosystem of therapeutic and diagnostic technologies used with Robotic Magnetic Navigation.

"Stereotaxis and MicroPort® EP are delighted to enter into this strategic collaboration and are confident it will benefit both companies along with the electrophysiologists and arrhythmia patients we serve," said David Fischel, CEO of Stereotaxis and Dr.Yiyong Sun, President of MicroPort® EP. "We look forward to providing China’s electrophysiology community with highly innovative and differentiated products that leverage Robotic Magnetic Navigation technology. This will both strengthen the importance of robotics and reinforce the key role of MicroPort® EP in this rapidly growing and underserved market.”

About Shanghai MicroPort® EP MedTech Co., Ltd

Shanghai MicroPort EP MedTech Co., Ltd. (MicroPort® EP) is a subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd. (stock code: 00853.HK). In the future, MicroPort® EP will continue to invest in research and development as well as product innovation, to create a product line encompassing active and passive solutions offered by both devices and equipment, with the aim of providing patients and doctors in the field of interventional therapy with accessible total medical solutions centering around precision navigation technologies.